Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

Other research analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. Wells Fargo & Company boosted their price objective on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. TD Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Milestone Pharmaceuticals in a research note on Tuesday, January 6th. Finally, Zacks Research cut shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Milestone Pharmaceuticals Trading Down 2.9%

Shares of MIST stock opened at $1.01 on Friday. The company has a quick ratio of 7.96, a current ratio of 8.01 and a debt-to-equity ratio of 1.37. The firm has a market cap of $118.85 million, a P/E ratio of -1.28 and a beta of 0.48. The company has a 50 day moving average of $1.70 and a 200-day moving average of $1.97. Milestone Pharmaceuticals has a 12-month low of $0.63 and a 12-month high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Friday, March 20th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. The firm had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $37.52 million. Sell-side analysts anticipate that Milestone Pharmaceuticals will post -0.62 earnings per share for the current year.

Insider Transactions at Milestone Pharmaceuticals

In other Milestone Pharmaceuticals news, CEO Joseph Oliveto sold 34,523 shares of the firm’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $1.93, for a total value of $66,629.39. Following the completion of the transaction, the chief executive officer owned 482,744 shares in the company, valued at $931,695.92. This trade represents a 6.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders sold 113,693 shares of company stock worth $233,347. Corporate insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sapient Capital LLC purchased a new stake in shares of Milestone Pharmaceuticals in the third quarter worth about $25,000. Strategic Family Wealth Counselors L.L.C. purchased a new position in Milestone Pharmaceuticals during the fourth quarter valued at approximately $25,000. Eaton Financial Holdings Company LLC purchased a new position in Milestone Pharmaceuticals during the fourth quarter valued at approximately $26,000. Bank of America Corp DE increased its holdings in Milestone Pharmaceuticals by 200,550.0% during the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after acquiring an additional 16,044 shares during the period. Finally, Stephenson & Company Inc. bought a new stake in Milestone Pharmaceuticals during the 3rd quarter worth approximately $40,000. 86.18% of the stock is currently owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.